Skip to main content
OpenTrials

Clinical trial condition

Histiocytic Disorders, Malignant

Explore clinical trials studying Histiocytic Disorders, Malignant. Study availability and eligibility vary by location and protocol.

271 public trials 44 recruiting studies
Refine in advanced search Browse all conditions

Histiocytic Disorders, Malignant trial results

Active, not recruiting

An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

NCT06734078

Conditions
DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
Locations
  • IRCCS Azienda Ospedaliero - Universitaria di Bologna Bologna, Italy
  • Casa Sollievo della Sofferenza - Reparto di Oncoematologia San Giovanni Rotondo, Foggia, Italy
  • Azienda Ospedaliera Universitaria- Policlinico di Bari Bari, Italy
  • Ospedale Oncologico Armando Businco Cagliari, Italy
View Trial Details
Active, not recruiting

Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT03064867

Conditions
Dendritic Cell Sarcoma, Interdigitating, Diffuse Large B-cell-lymphoma, Hemic and Lymphatic Diseases, +5 more
Locations
  • Washington University School of Medicine, Siteman Cancer Center St Louis, Missouri, United States
  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
View Trial Details
Completed

DPX-Survivac and Checkpoint Inhibitor in DLBCL

NCT03349450

Conditions
Adult Diffuse Large Cell Lymphoma, Adult Refractory Diffuse Large B-Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, +18 more
Locations
  • Tom Baker Cancer Centre - Alberta Health Services Calgary, Alberta, Canada
  • Nova Scotia Health Authority: Queen Elizabeth II Health Sciences Centre Halifax, Nova Scotia, Canada
  • London Health Sciences Centre London, Ontario, Canada
  • Ottawa Hospital Research Institute Ottawa, Ontario, Canada
View Trial Details
Completed

Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life

NCT06026644

Conditions
DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
Locations
  • Aou Di Bologna - Policlinico S. Orsola-malpighi - Uoc Ematologia Bologna, Italy
  • Asst Degli Spedali Civili Di Brescia - Ssvd Centro Trapianti Midollo Per Adulti - Cattedra Di Ematologia Brescia, Italy
  • AOU Careggi - SOD terapie cellulari e Medicina Trasfusionale Florence, Italy
  • Irccs Aou San Martino - Genova - Uo Ematologia E Trapianti Genova, Italy
View all 13 locations
View Trial Details
Completed

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

NCT02220985

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, +57 more
Locations
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details

Related conditions